The new Medicare GLP-1 Bridge gives eligible Part D beneficiaries access to certain GLP-1 weight-loss medications for $50 per month
Product specifications may change without notice, and it is the responsibility of the purchaser, user, or importer of record to verify the accuracy and suitability of the product at the time of ordering
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants
These follow-on patents extend the patent protection for Mounjaro and Zepbound until 2041 and it is likely that more follow-on patents will be added in the coming years
It is typically administered as an IV push at around 1400mg